BioSpace News Archive

Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today the appointment of Thomas Bonnefont to the newly created position of Chief Operating and Commercial Officer of the iBiopsy® Business Unit as well as the appointment of Mike Doherty as Sr. Strategy

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

The National Marrow Donor Program® /Be The Match® announced plans to launch the ACCESS clinical trial titled A Multicenter Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.

Ten grants from the American Diabetes Association and the American Heart Association’s joint initiative aim to decrease heart disease and stroke among people with type 2 diabetes

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or the “Company”).

Synaptogenix, Inc., an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that it will attend two upcoming scientific industry conferences.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of a research paper in the Journal of Controlled Release.

Today, leaders of 50 organizations and patient groups announced the formation of the Long COVID Alliance.

The University of California, San Francisco (UCSF) and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS)

By 2024, the North America molecular diagnostics market share is slated to surpass USD 5.3 billion annually.